Bota - About the company
Bota is a series B company based in Lafayette (United States), founded in 2019 by Cheryl Cui. It operates as a Developer of AI-based platform for enzyme and strain engineering. Bota has raised $100M in funding from investors like BASF, CMB International Capital and Matrix Partners China. The company has 69 active competitors, including 20 funded and 14 that have exited. Its top competitors include companies like Senti Bio, CRISPR Therapeutics and ADARx Pharmaceuticals.
Company Details
Developer of AI-based platform for enzyme and strain engineering. This technology is used for producing microbe-based products in industries and also helps in fermentation. The engineered enzymes and strains are developed to tolerate harsh environments, eliminate the accumulation of intermediates, and increase productivity. The company has also developed a fermentation process for producing engineered strains and enzymes.
- Website
- bota.bio
Key Metrics
Founded Year
2019
Location
Lafayette, United States
Stage
Series B
Total Funding
$100M in 2 rounds
Latest Funding Round
Ranked
6th among 69 active competitors
Employee Count
45 as on Sep 30, 2026
Legal entities associated with Bota
Bota is associated with 1 legal entity given below:
Legal Entity Name | Date of Incorporation | Revenue | Latest Employee Count | Reports |
|---|---|---|---|---|
BOTA BIOSCIENCES, INC. CIN: 843230706 , United States, Active | Dec 31, 1999 | - | 7 (As on Dec 31, 2024) | - |
Sign up to download Bota's company profile
Bota's funding and investors
Bota has raised a total funding of $100M over 2 rounds. Its first funding round was on Mar 16, 2021. Its latest funding round was a Series B round on Jul 29, 2021 for $*****. 7 investors participated in its latest round. Bota has 11 institutional investors.
Here is the list of recent funding rounds of Bota:
Date of Funding | Funding Amount | Round Name | Post-Money Valuation | Revenue Multiple | Lead Investors | Other Investors |
|---|---|---|---|---|---|---|
Jul 29, 2021 | 4514625 | Series B | 5815403 | 3627036 | 4277320 | 6606033 |
Mar 16, 2021 | 7300584 | Seed | 8485872 | 8788442 | 5823480 |
View details of Bota's funding rounds and investors
Bota's founders and board of directors
Founder? Claim ProfileThe founders of Bota is Cheryl Cui.
Here are the details of Bota's key team members:
- Cheryl Cui: Co-Founder of Bota. Contact Info: 1 email address
View details of Bota's Founder profiles and Board Members
Bota's employee count trend
Bota has 45 employees as of Sep 26. Here is Bota's employee count trend over the years:
Access Tracxn on any website
Install Tracxn ExtensionOur Google Chrome extension lets you view company details while browsing their websites
Bota's Competitors and alternates
Top competitors of Bota include Senti Bio, CRISPR Therapeutics and ADARx Pharmaceuticals. Here is the list of Top 10 competitors of Bota, ranked by Tracxn score:
Get insights and benchmarks for competitors of 2M+ companies! Sign up today!
Rank | Company Details | Short Description | Total Funding | Investors | Tracxn Score |
|---|---|---|---|---|---|
1st | Senti Bio 2016, San Francisco (United States), Public | Developer of cell and gene therapies for patients living with incurable diseases | $158M | 72/100 | |
2nd | CRISPR Therapeutics 2013, Basel (Switzerland), Public | Developer of solutions for treating human genetic diseases by using genome editing technology | $127M | 63/100 | |
3rd | ADARx Pharmaceuticals 2019, San Diego (United States), Public | Developer of genetic therapeutic solutions to edit single point mutations on RNA transcripts | $353M | 61/100 | |
4th | Geninus 2018, Seoul (South Korea), Public | Developer of genomic-based disease prevention platform | $13.3M | 61/100 | |
5th | Genprex 2009, Austin (United States), Public | Developer of therapeutics to treat cancer at molecular level | $3.11M | 56/100 | |
6th | Bota 2019, Lafayette (United States), Series B | Developer of AI-based platform for enzyme and strain engineering | $100M | 57/100 | |
7th | Provider of non-viral cell engineering technology platform for drug discovery | $33.5M | 54/100 | ||
8th | Modular Genetics 2000, Woburn (United States), Series B | Developer of a proprietary, automated system for gene engineering and molecular biology | $8.9M | 52/100 | |
9th | GeneScience Pharmaceuticals 1996, Changchun (China), Series B | Provides genetically engineered pharmaceuticals products | - | 50/100 | |
10th | Poseida Therapeutics 2015, San Diego (United States), Acquired | Developer of gene therapies for treating cancer and liver orphan disease by using gene editing technologies | $324M | 50/100 |
Looking for more details on Bota's competitors? Click here to see the top ones
Bota's Investments and acquisitions
Bota has made no investments or acquisitions yet.
Reports related to Bota
Here is the latest report on Bota's sector:
News related to Bota
Media has covered Bota for a total of 3 events in the last 1 year, 3 of them have been about company updates.
•
•
Bota Bio Rebrands as Enhe Technology and Launches AI Biomanufacturing Platform SAION AIPandaily•Mar 10, 2026•Bota, NA
•
•
•
Bota Bio Raises New Capital to Popularize Biological ManufacturingCaixin Global•Jul 30, 2021•Bota, Sequoia Capital, Matrix Partners China, Source Code Capital and 2 others
•
Sustainable Biomanufacturing Co. Grabs $100M In Series BLaw360•Jul 29, 2021•Bota, Sequoia Capital, 5Y Capital, Sherpa Healthcare Partners and 5 others
•
•
Are you a Founder ?
FAQs about Bota
Explore our recently published companies
- Nic Beddoe Insurance - Truckee based, Unfunded company
- Jerry Tench Insurance - San Francisco based, Unfunded company
- Cesar Carrillo Insurance - Island Lake based, Unfunded company
- Clinton Raines - Atlanta based, Unfunded company
- Brian Himmelman State Farm - Conifer based, Unfunded company
- Curt Sumpter State Farm - Silver Spring based, Unfunded company